US Stock Insider Trading | IDEAYA Biosciences Discloses 4 Insider Transactions on February 2

K-LinePoet · 2026-02-04T20:22:05+00:00

On February 2, 2026, IDEAYA Biosciences disclosed multiple insider transactions, with executive Ruiz Briseno Andres purchasing 1,253 shares on November 28, 2025. Additionally, other executives and directors have conducted multiple buy and sell transactions. IDEAYA is a precision medicine company focused on oncology.

K-LinePoet

2026-02-04 20:22:05

Abstract generation in progress

February 2, 2026, IDEAYA Biosciences (IDYA) disclosed four insider trading transactions. Executive Ruiz Briseno Andres purchased 1,253 shares on November 28, 2025.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 2, 2026	Executive	Ruiz Briseno Andres	November 28, 2025	Buy	1253	16.91	$21,200
February 2, 2026	Executive	Snyder Douglas B.	November 28, 2025	Buy	2080	16.91	$35,200
February 2, 2026	Executive	Ruiz Briseno Andres	November 29, 2024	Buy	682	23.26	$15,900
February 19, 2025	Director	Hata Yujiro S	February 18, 2025	Buy	12,800	19.52	$250,000
June 27, 2024	Executive	Throne Jason	June 27, 2024	Buy	47,100	7.01	$329,900
June 27, 2024	Executive	Throne Jason	June 27, 2024	Buy	6,424	13.34	$85,700
May 31, 2024	Executive	WHITE MICHAEL ANTHONY	May 29, 2024	Sell	27,600	36.23	$1,001,600
May 31, 2024	Executive	WHITE MICHAEL ANTHONY	May 29, 2024	Buy	28,500	12.86	$368,500
May 31, 2024	Executive	WHITE MICHAEL ANTHONY	May 29, 2024	Sell	851	36.78	$31,300
May 16, 2024	Director	Hata Yujiro S	May 16, 2024	Sell	30,100	41.73	$1,255,500

【Company Profile】

IDEAYA Biosciences, Inc., headquartered in South San Francisco, California, was incorporated in Delaware in June 2015. The company is a precision medicine firm focused on oncology, dedicated to discovering and developing targeted therapies for patient populations selected through molecular diagnostics. Their approach combines extensive capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient groups most likely to benefit from their targeted therapies under development. They are applying these capabilities across various precision medicine areas, including direct targeting of oncogenic pathways and synthetic lethality, representing an emerging class of precision medicine targets.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.